h1

TY  - THES
AU  - Cromme, Tina Andrea
TI  - Die Sequenztherapie beim metastasierten Nierenzellkarzinom : Auswertung des Patientenkollektivs am UK Aachen bis Oktober 2011, eingebettet in eine Metaanalyse relevanter Arbeiten zu den Sequenzierungen Sorafenib-Sunitinib und Sunitinib-Sorafenib
PB  - Rheinisch-Westfälische Technische Hochschule Aachen
VL  - Dissertation
CY  - Aachen
M1  - RWTH-2021-10174
SP  - 97 Seiten : Diagramme
PY  - 2021
N1  - Dissertation, Rheinisch-Westfälische Technische Hochschule Aachen, 2021
AB  - Since targeted agents were first launched in 2005 the prognosis for patients with metastatic renal cell carcinoma improved significantly. In the past many questions concerning the most beneficial sequencing of the different agents arose, were partly answered, partly dismissed and partly remain to be answered by strong data. For the present study, the data of 20 patients who were treated with the sequence Sunitinib-Sorafenib at Aachen University hospital until October 2011 were retrospectively captured and analyzed. Subsequently the results were put into perspective and compared to similar studies identified on Pubmed. In the present study, the median time to progression under Sunitinib was 12.7 months and the median time to progression under Sorafenib 5.5 month. The time to second progression from the start of the first agent until progress/censoring on the second was 21.7 months. The longest combined progression free survival for the reciprocal sequence in compared studies was 18.2 months. The results of the present study compared to published data suggest that there is no advantage to either sequence for the whole collective of patients. Nevertheless, for the subgroup of patients older than 65 years of age, the present data shows a significant lesser value in comparison to the whole collective for the sequence applied. This supports the results of the subgroup analysis of the SWITCH-study which found a possible superiority of the sequence Sorafenib-Sunitinib for patients older than 65. Moreover, the results of the present study support the hypothesis that TSH could be used as a predictive biomarker in order to evaluate a response to therapy. 61.5
LB  - PUB:(DE-HGF)11
UR  - https://publications.rwth-aachen.de/record/834834
ER  -